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T helper 17 (Th17) cell development is driven by cyto-
kines including transforming growth factor-b (TGF-b),
interleukin-6 (IL-6), IL-1, and IL-23. Regulatory T
(Treg) cells can provide the TGF-b in vitro, but their
role in vivo remains unclear, particularly because
Treg cells inhibit inflammation in many models of
Th17 cell-associated autoimmunity. We used mice
expressing Diphtheria toxin receptor under control
of the Foxp3 promoter to deplete Foxp3+ Treg cells
in adult mice during in vivo Th17 cell priming. Treg
cell depletion resulted in a reduced frequency of
antigen-specific IL-17 producers in draining lymph
nodes and blood, correlating with reduced inflamma-
tory skin responses. In contrast, Treg cells did not
promote IL-17 secretion after initial activation
stages. Treg cell production of TGF-b was not
required for Th17 cell promotion, and neither was
suppression of Th1 cell-associated cytokines.
Rather, regulation of IL-2 availability and resultant
signaling through CD25 by Treg cells was found to
play an important role.
INTRODUCTION
The balance between inflammatory and regulatory factors is vital
to prevent tissue damage during infection and in the control of
detrimental responses to self-antigen. T helper 1 (Th1) and T
helper 17 (Th17) cells promote inflammation through their
production of cytokines such as interferon-g (IFN-g), inter-
leukin-17 (IL-17), and IL-22. On the other hand, Foxp3+ regula-
tory T cells control inflammation through multiple mechanisms
including production of the cytokine IL-10 and transforming
growth factor-b (TGF-b). TGF-b suppresses the putative Th1
cell transcription factor T-bet, as well as IFN-g production (Lin
et al., 2005; Park et al., 2005). TGF-b also promotes development
andmaintenance of Foxp3+ regulatory T cells (Marie et al., 2005),
and mice in which T cells cannot respond to TGF-b succumb
to lethal inflammatory disease largely dominated by Th1 cells(Fahlen et al., 2005; Li et al., 2006). It was somewhat unexpected
then that TGF-b, when combined with inflammatory cytokines
such as IL-6, was shown to promote Th17 cell development at
the expense of Treg cell development in vitro (Bettelli et al.,
2006; Mangan et al., 2006; Veldhoen et al., 2006a). However,
the role of TGF-b in Th17 cell development remains controver-
sial, particularly for human T cells (Boniface et al., 2008).
In addition to induction by TGF-b (with inflammatory cytokines
acting as a switch factor), Treg and Th17 cell development share
several other common themes. It has been suggested that the
transcription factors Foxp3 and RORgt are concomitantly upre-
gulated in developing Th17 cells by TGF-b and that further
signals, such as IL-6 and IL-23, are required to prevent Foxp3
from suppressing RORgt expression (Zhou et al., 2008). This
scenario appears most relevant in the gut, where high concen-
trations of TGF-b regulate responses to commensal bacteria
and T cells expressing both RORgt and Foxp3 are most readily
found (Zhou et al., 2008). In addition, cytokines that promote
Th17 cell development (including IL-6 and TNF-a) inhibit the
function of Treg cells to allow effector responses that are
required during infection (Pasare and Medzhitov, 2003; Valencia
et al., 2006). In contrast, Treg cells are highly dependent on IL-2
for survival (Setoguchi et al., 2005), whereas Th17 cell responses
are inhibited by IL-2 (Laurence et al., 2007).
The sources of TGF-b for Th17 cell induction remain unclear
but there are suggestions that T cells and possibly Treg cells
may be involved. In vitro, Foxp3+ regulatory T cells are a sufficient
source of TGF-b for induction of RORgt and IL-17, demonstrated
by the requirement for addition of exogenous TGF-b in Treg cell-
deficient cultures (LeibundGut-Landmann et al., 2007; Veldhoen
et al., 2006a). In vivo, Veldhoen and colleagues have used T cell-
restricted TGF-b receptor (TGF-bR) deficiency to show that
TGF-b acts directly on T cells for Th17 cell induction (Veldhoen
et al., 2006b). Furthermore, Li et al. (2007) restricted TGF-b defi-
ciency to T cells to show that T cells are an important source of
TGF-b in vivo. However, these studies do not define which T cell
population produces TGF-b to promote Th17 cell induction nor
whether this source is required throughout the response or
only at certain stages of Th17 cell development. Furthermore,
results are complicated by the large Th1 cell-mediated inflam-
matory responses that develop in these mice, because it is
known that Th1 cell-related cytokines (IL-12, IFN-g) suppress
Th17 cell development (McGeachy and Cua, 2008). The preciseImmunity 34, 409–421, March 25, 2011 ª2011 Elsevier Inc. 409
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remain unclear, and one recent report suggests that TGF-b func-
tions indirectly to inhibit Th1 cell and Th2 cell responses (Das
et al., 2009), thereby facilitating the emergence of the Th17 cell
phenotype.
Mice genetically deficient for functional Foxp3 expression
develop lethal inflammatory disease at an early age (Fontenot
et al., 2003; Khattri et al., 2003), limiting their usefulness. We
therefore used a model in which Foxp3-expressing T cells could
be depleted in healthy adult mice. Foxp3.luciDTR mice carry a
bacterial artificial chromosome transgene expressing Diphtheria
toxin receptor (DTR), green fluorescent protein (GFP), and Click
Beetle luciferase, under control of the Foxp3 promoter (Suffner
et al., 2010). Several lines of these mice were created with
differing expression of the transgene. Foxp3.luciDTR4 mice
deplete 90% to 95% of Foxp3+ cells after DT administration
without any overt signs of ill health or weight loss, although
immune activation is evident in lymphoid tissues (Suffner et al.,
2010). In contrast, administration of DT to Foxp3.luciDTR5
mice yields greater than 99%depletion of Treg cells. In this study
we made use of these mouse strains to deplete the majority of
Foxp3+ regulatory T cells at defined time points in vivo, to inves-
tigate the requirements for Treg cells during development of
Th17 cells in healthy adult animals. In immunized mice, the
Foxp3+ Treg cell population returned to normal numbers remark-
ably fast, within 1 week after depletion, giving a narrow time
frame in which Treg cells were reduced. The proportion of
IL-17-producing OT-II cells was reduced when Treg cells were
depleted at the time of immunization but not at later time points.
Also, Th17 cells underwent normal development in a recently
activated lymph node (LN) environment, further suggesting that
the important factor was the absence of Treg cells at the time
of Th17 cell initiation rather than the inflammation elicited by
the absence of Treg cells. Finally, we found that IL-2 rather
than IL-12 or IFN-g was a key cytokine in mediating these
effects. These findings demonstrated that Foxp3+ regulatory
T cells promoted rather than inhibited Th17 cell differentiation
in vivo and that this effect occurred only during early phases of
Th17 cell development.
RESULTS
Depletion of Treg Cells Inhibits Th17 Cell Priming
and Effector Responses In Vivo
We have previously established conditions to track the develop-
ment of antigen-specific Th17 cells in vivo by using transgenic
OT-II T cells and immunization with ovalbumin peptide 323-339
(OVA323-339) in complete Freund’s adjuvant (CFA) (McGeachy
et al., 2009). To investigate the contribution of regulatory
T cells, we transferred OT-II T cells into Foxp3.luciDTR4 recipient
mice and administered Diphtheria toxin (DT) to deplete regula-
tory T cells at the time of immunization with OVA(323-339) in
CFA. Seven days after immunization, it was clear that the propor-
tion of IL-17+ T cells was greatly reduced in Treg cell-depleted
compared to nondepleted hosts (Figures 1A and 1B). To rule
out the possibility that Diphtheria toxin directly influenced
Th17 cell development (for example through adjuvant-related
activities), wild-type recipient mice that did not bear the high-
affinity Diphtheria toxin receptor were also given DT at the time410 Immunity 34, 409–421, March 25, 2011 ª2011 Elsevier Inc.of immunization. No difference in IL-17 induction was observed
when wild-type recipient mice received DT, compared to wild-
type or Foxp3.luciDTR4 mice that did not receive DT (data
not shown). This confirmed that Th17 cell development is not
directly affected by Diphtheria toxin but rather by the depletion
of Treg cells.
Administration of DT to Foxp3.luciDTR4 mice depletes
90%–95% of Treg cells (Suffner et al., 2010). We hypothesized
that the remaining 5%–10% could partially compensate to
induce some IL-17. We therefore also tested the ability of
Th17 OT-II cells to differentiate in Foxp3.luciDTR5 mice, which
deplete >99% of Treg cells after DT administration (Suffner
et al., 2010). IL-17 induction was again significantly impaired,
both by percentage of OT-II cells expressing IL-17 and by abso-
lute numbers of IL-17+OT-II cells permouse (Figures 1C and 1D).
However, the frequency of IL-17+ cells was not further
decreased in thesemice compared to Foxp3.luciDTR4, suggest-
ing that some Th17 cells can develop in the absence of Treg
cells.
To further confirm that Treg cells can promote the develop-
ment of Th17 cells in vivo, we performed transfers of CD25-
depleted OT-II cells into RAG-deficient hosts, which lack B
and T cells, including regulatory T cells. When CD4+CD25+
Treg cells, but not CD4+CD25– cells, were cotransferred with
OT-II cells, there was an enhanced IL-17 response compared
to OT-II cells transferred alone (Figure 1E).
To test whether the reduced IL-17 that we observed when
Treg cells were depleted correlated with functional changes,
we used the delayed-type hypersensitivity (DTH) response as
a functional readout. Mice in which Treg cells were depleted at
time of immunization displayed a significantly reduced DTH
response after challenge with ovalbumin in the footpad (Fig-
ure 1F; Figure S1 available online). We also observed reduced
frequencies of both total OT-II+ cells and IL-17+OT-II+ cells in
the blood of Treg cell-depleted mice compared to nondepleted
(Figures 1G and 1H), suggesting that the reduced DTH response
was due to fewer Th17 cells available to enter peripheral tissue
sites and establish inflammation. Taken together, these data
suggested that the reduced IL-17 seen when OT-II cells were
primed in the absence of Treg cells correlated with reduced
inflammatory potential at the population level.
Foxp3+ Regulatory T Cells Are Not Required for Th17
Cell Maintenance In Vivo
These data showed that Foxp3+ Treg cells promote Th17 cell
development during initial priming events in vivo. We next inves-
tigated whether in vivo IL-17 production was affected by
loss of regulatory T cells at later points of differentiation.
Foxp3.luciDTR4 recipients of OT-II cells were immunized with
OVA(323-339) as before, and Treg cells were depleted starting
on either day 1, day 2, or day 4 postimmunization. Analysis
of GFP+ cells on day 7 postimmunization showed efficient deple-
tion by DT and there was only a very slight restoration of GFP+
cells in the mice that received DT on day 1 compared to
day 4 (Figure 2A). However, percentages of all Foxp3+ cells
were not significantly different between untreated controls and
mice that received DT at day1, although theywere still reduced
in mice that received DT on days 2 and 4 postimmunization (Fig-
ure 2B). These results correlatedwith the findings of Suffner et al.
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Figure 1. Depletion of Treg Cells during T Cell Priming Reduces Th17 Cell Development
CD4+CD25–CD45.1+ OT-II cells were transferred into wild-type (control), Foxp3.luciDTR4, or Foxp3.luciDTR5 CD45.2+ recipients 1 day before immunization with
OVA(323-339) in CFA. Mice received DT on day 1 and day 0 postimmunization.
(A and B) Draining LN cells from Foxp3.luciDTR4 recipients were analyzed on day 7 by flow cytometry for intracellular cytokine expression in CD4+CD45.1+ OT-II
cells after stimulation with PMA and ionomycin.
(C and D) Draining LN cells from Foxp3.luciDTR5 recipients were analyzed on day 7 by flow cytometry for intracellular cytokine expression in CD4+CD45.1+ OT-II
cells after stimulation with PMA and ionomycin. Percentage and absolute numbers of IL-17+ cells are shown. Data shown are pooled from three separate
experiments with two to three mice per group, mean ± SD.
(E) CD4+CD25 OT-II cells were transferred into RAG-deficient animals either alone or at a 1:1 ratio with B6 CD4+CD25+ or CD4+CD25 cells as indicated.
(F) Control or Foxp3.luciDTR4 recipients were challenged with ovalbumin in one hind footpad on day 8 postimmunization, and the contralateral footpad received
saline. DTH response is expressed as change in thickness of ovalbumin-challenged foot relative to saline-challenged foot measured 24 hr after challenge.
(G and H) Draining LN cells and blood were analyzed by flow cytometry on day 10 postimmunization for frequency of OT-II cells and intracellular IL-17 expression
by OT-II cells after stimulation with PMA and ionomycin. Data show mean ± SD, representative of two to four experiments with three to four mice per group.
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Figure 2. Treg Cells Promote Early IL-17 Induction but Not Maintenance
(A–C) CD4+CD25– OT-II cells were transferred into wild-type or Foxp3.luciDTR4 recipients 1 day before immunization with OVA(323-339). Mice received two
injections of Diphtheria toxin (DT) given 24 hr apart starting on day 1, day 2, or day 4; a fourth control group received PBS. Draining LN cells were analyzed on
day 7 postimmunization for (A) GFP expression in total CD4+ cells, (B) Foxp3 expression in CD4+ cells, and (C) IL-17 expression in CD4+CD45.1+ OT-II cells after
ex vivo stimulation with PMA and ionomycin.
(D) Th17 cells were generated in vitro by stimulation of OT-II cells with OVA(323-339) in the presence of TGF-b and IL-6. IL-17 expression was analyzed by
intracellular cytokine staining after PMA and ionomycin stimulation on day 9 of culture.
(E) 1.5 million in vitro polarized Th17 OT-II cells were transferred into wild-type or Foxp3.luciDTR4 recipients, and mice were immunized with OVA(323-339) 1 day
later and receivedDiphtheria toxin (DT) on days1 and 0. CD4+CD45.1+ OT-II cells were stained for intracellular IL-17 after ex vivo stimulation of draining LN cells
with PMA and ionomycin on day 7 after immunization.
(F) Three million in vitro polarized Th17 OT-II cells were transferred into wild-type or Foxp3.luciDTR4 recipients andmice received DT on day of transfer and 1 day
later. CD4+CD45.1+ OT-II cells were stained for intracellular IL-17 after ex vivo stimulation of spleen cells with PMA and ionomycin on day 7 after transfer.
All data shown are representative of two to three similar experiments with three to four mice per group; some data are pooled from multiple experiments;
horizontal bars indicate mean.
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Treg Cells Promote Th17 Cells In Vivo through IL-2(2010) in nonimmunized mice: after DT administration, the
remaining GFP-negative (and therefore DTR-negative) Foxp3+
cells undergo homeostatic expansion to replace their depleted
GFP+ counterparts. However, it appeared that in mice immu-
nized with peptide in CFA, this expansion was accelerated,
because the Treg cell population size had completely recovered
by day 7 in our study, whereas in nonimmunized mice this
recovery takes 2 weeks (Suffner et al., 2010).
Depletion of regulatory T cells on day 2 postimmunization led
to reduced frequencies of IL-17+ OT-II cells analyzed on day 7,
similar to results when Treg cells were depleted at the time of
immunization (Figure 2C). However, depletion of Treg cells on
day 4 had no effect on subsequent IL-17 production. Therefore,
the data are consistent with a requirement for Treg cells during
the initial activation of Th17 cells, but that after 4 days the pres-
ence of regulatory T cells no longer promotes Th17 cell develop-
ment. Because there was also no increase in the frequency of
IL-17+ cells in mice where Treg cell numbers were still low412 Immunity 34, 409–421, March 25, 2011 ª2011 Elsevier Inc.(comparing depletion on day 4 versus day 1), it seems that
Treg cells are also not required to regulate late Th17 cell
expansion.
To further investigate whether Treg cells promote long-term
Th17 cell maintenance in vivo, we generated Th17 cells in vitro
by activating OT-II T cells with OVA(323-339) in the presence
of TGF-b, IL-6, anti-IFN-g, and anti-IL-2. This resulted in more
than 70% of the T cells producing IL-17 (Figure 2D), and these
cells were transferred into recipient Foxp3.luciDTR4 mice that
were then immunized with OVA(323-339) in CFA to further acti-
vate the cells in the presence of inflammatory cytokines including
IL-23. Depletion of Treg cells at the time of immunization did not
have any effect on maintenance of IL-17 production (Figure 2E).
In nonimmunized control mice, the overall frequencies of IL-17+
cells were lower compared to immunized mice, and the absence
of Treg cells did result in a slight decrease in IL-17 production
7 days after transfer (Figure 2F). This suggested that there was
a minimal requirement for Treg cells during later activation and
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Figure 3. Treg Cell Depletion at Time of Immunization Enhances Activation of Recipient Foxp3+ and Foxp3–CD4+ Cells
(A) CD4+CD25– OT-II cells were transferred into wild-type or Foxp3.luciDTR4 recipients 1 day before immunization with OVA(323-339). Mice received two
injections ofDiphtheria toxin (DT) starting on day1, day 2, or day 4, and a fourth group received PBS. Draining LN cells were analyzed on day 7 postimmunization
and CD44hi cells are expressed as a percentage of CD4+Foxp3+ Treg cells.
(B–F) CD4+CD25– OT-II cells were transferred into wild-type, Foxp3.luciDTR4, or Foxp3.luciDTR5 recipients 1 day before immunization with OVA(323-339), and
Diphtheria toxin (DT) was given on day 1 and 0. Frequency of CD44hi cells was assessed in endogenous CD4+ T cells (negative for expression of Foxp3 and
CD45.1) in Foxp3.luciDTR4 (B) and Foxp3.luciDTR5 (C) recipients. Percentage of OT-II cells out of total CD4+ cells in Foxp3.luciDTR4 (D) and Foxp3.luciDTR5 (E)
recipients. Absolute number of OT-II cells in draining LN cells of Foxp3.luciDTR5 recipients shown in (F).
Data are representative of at least three independent experiments with two to four mice per group; horizontal bars indicate mean.
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Treg Cells Promote Th17 Cells In Vivo through IL-2maintenance of Th17 cells in vivo, particularly under inflamma-
tory conditions, correlating with the finding that depleting Treg
cells at day 4 postimmunization had little effect.
Th17 Cells Can Develop in the Presence of Highly
Activated Regulatory T Cells
Homeostatic or activation-induced expansion of regulatory
T cells is known to increase their activation state and ability to
suppress (Gavin et al., 2002; Tarbell et al., 2004). Indeed,
Foxp3+ cells that had homeostatically expanded after DT admin-
istration had increased expression of the activationmarker CD44
(Figure 3A), again confirming observations made in nonimmu-
nized mice (Suffner et al., 2010). It could therefore be argued
that the presence of highly activated Treg cells at day 7 corre-
lateswith reduced IL-17 observed at that time point. On the other
hand, the proportion of endogenous (CD45.1–) Foxp3–CD4+
T cells that were CD44hi was also increased after Treg cell deple-
tion in both Foxp3.luciDTR4 and Foxp3.luciDTR5 recipients
(Figures 3B and 3C). This suggested that OT-II cells could face
increased competition from endogenous T cells for access to
antigen, costimulatory molecules, and cytokines produced by
dendritic cells. Indeed, the frequency and number of OT-II cellswas somewhat reduced when Treg cells were depleted at
the time of immunization in both lines of Foxp3.luciDTR mice
(Figures 3D–3F), suggesting reduced expansion of OVA-specific
T cells.
We therefore set out to test whether the LN environment that
was generated when Treg cells were depleted at time of immu-
nization contributed to the reduced IL-17 in OT-II cells. Wild-
type and Foxp3.luciDTR4 mice were immunized as before with
OVA(323-339) in CFA and received DT on day 1 and day 0.
However, OT-II cells were not transferred until day 6 postimmu-
nization. Thus, the Th17 cells were differentiated in the presence
of either highly active recently expanded Treg cells or ‘‘normal’’
Treg cells (in nondepleted mice). Analysis on day 6 after
transfer (day 12 postimmunization) showed that OT-II cells had
expanded equally well in Foxp3.luciDTR4 and wild-type mice
(Figure 4A), despite the presence of higher frequencies CD44hi
cells in both Foxp3+ and Foxp3– T cell populations (Figures 4B
and 4C). Importantly, the presence of recently expanded Treg
cells did not inhibit the induction of IL-17 (Figures 4D and 4E).
To further test whether the hyperactivated LN environment
induced by depletion of Treg cells contributed to inhibition of
IL-17, we depleted Treg cells and immunized mice with OVAImmunity 34, 409–421, March 25, 2011 ª2011 Elsevier Inc. 413
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Figure 4. IL-17 Induction Is Not Inhibited by Presence of Activated Endogenous T Cells and Treg Cells
(A–E)Wild-type and Foxp3.luciDTR4micewere immunizedwith OVA(323-339) and received DT on days1 and 0. On day 6, immunizedmice receivedOT-II cells.
Draining LN cells were analyzed by flow cytometry on day 12 postimmunization.
(A–C) CD45.1+ OT-II cells shown as a percentage of CD4+ cells (A), percentage of Foxp3+ CD4+ cells that are CD44hi (B), percentage of CD4+ cells, excluding
Foxp3+ and OT-II+ cells, that are CD44hi (C).
(D and E) Intracellular IL-17 staining in OT-II cells after ex vivo stimulation with PMA and ionomycin.
(F and G) Wild-type and Foxp3.luciDTR4 mice were immunized with OVA(323-339) and received DT on days1 and 0. On day 3, immunized mice received OT-II
cells. Draining LN cells were analyzed by flow cytometry on day 10 postimmunization for OT-II frequency (F) and intracellular IL-17 expression in OT-II cells after
ex vivo stimulation with PMA and ionomycin (G).
Data are pooled from two independent experiments with three to five mice per group; horizontal bars indicate mean.
Immunity
Treg Cells Promote Th17 Cells In Vivo through IL-2(323-339) in CFA, then transferred OT-II cells 3 days later. Again,
expansion of OT-II cells was comparable to recipients that were
not subjected to Treg cell depletion (Figure 4F). Surprisingly,
IL-17 production was enhanced in OT-II cells transferred into
mice depleted of Treg cells 3 days earlier compared to controls414 Immunity 34, 409–421, March 25, 2011 ª2011 Elsevier Inc.(Figure 4G). These results suggested that Treg cell depletion did
not inhibit IL-17 indirectly because of nonspecific bystander cell
activation, but rather the activated environment and/or the pres-
ence of expanding Treg cells on day 3 postimmunization actually
enhanced Th17 cell development.
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Figure 5. Th17 Cell Development Does Not Require Treg Cell-Produced TGF-b or Suppression of IFN-g
(A and B) CD4+CD25– OT-II cells were transferred into wild-type or Tgfb1f/n Foxp3-cre recipients 1 day before immunization with OVA(323-339). Draining LN cells
were analyzed for intracellular cytokine expression after stimulation with PMA and ionomycin on day 7 postimmunization. Graph in (B) shows data pooled from
two experiments; horizontal bars indicate mean.
(C–E) CD4+CD25– OT-II cells were transferred into wild-type or Foxp3.luciDTR4 recipients 1 day before immunization with OVA(323-339). Mice received two
injections ofDiphtheria toxin (DT) given 24 hr apart starting on either day1, day 2, or day 4; a fourth group received PBS. Draining LN cells were analyzed on day
7 postimmunization. The proportion of OT-II cells expressing IFN-g only (C) or both IFN-g and IL-17 (D) was analyzed by intracellular staining after stimulation with
PMA and ionomycin. In (E), mice received 1mg anti-IFN-g or isotype control antibody on day of immunization, and IL-17 expression in OT-II cells was analyzed on
day 7 postimmunization. Data shown in (C) and (D) are representative of three separate experiments; (E) shows data pooled from two experiments.
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Cell-Produced TGF-b or Suppression of Th1
Cell-Associated Cytokines
It has previously been shown that CD4+ T cell production of
TGF-b is crucial for Th17 cell development in vivo (Li et al.,
2007). Given that regulatory T cells are a source of TGF-b in vitro
(Veldhoen et al., 2006a), it seemed likely that they could also be
the source of TGF-b in vivo. To restrict TGF-b deficiency to the
regulatory T cell population, Tgfb1f/n mice were crossed with
Foxp3-cre mice. The resulting Tgfb1f/n Foxp3-cre mice were
used as recipients for OT-II CD4+CD25 T cells. Surprisingly,
Treg cell-specific depletion of TGF-b did not have any impact
on IL-17 production by the OT-II T cells (Figures 5A and 5B), sug-
gesting that Treg cells were not required to produce TGF-b for
Th17 cell development in vivo.
Treg cells may also inhibit Th1 cell responses. In contrast to
IL-17+ cells, frequencies of IFN-g+ and IFN-g+IL-17+ cells were
not reduced when Treg cells were depleted, nor increased
when Treg cells were cotransferred with OT-II cells into RAG-
deficient animals (Figures 5C and 5D, and data not shown),suggesting that the defect was specific to Th17 cell induction.
Treg cell deficiency has been reported to enhance IFN-g, but
we did not consistently observe this, most probably because
of the rapid expansion of Treg cells in our model compared to
longer-lasting antibody or genetic depletions. Both IL-12 and
IFN-g are known to inhibit Th17 cell induction (McGeachy and
Cua, 2008), and we hypothesized that Treg cells may reduce
production of these Th1 cell-associated cytokines to allow
Th17 cell priming. However, mRNA analysis of CD11c+ dendritic
cells isolated from draining LN cells day 3 postimmunization did
not show any difference in IL-12p35 nor of IL-23 in the presence
or absence of Treg cells (Figure S2A). Furthermore, administra-
tion of neutralizing anti-IFN-g was unable to restore IL-17
production (Figure 5E), and IFN-gR-deficient OT-II cells also
showed impaired IL-17 production in the absence of Treg cells
(Figure S2B). Use of IL-12p35-deficient Foxp3.luciDTR4 recipi-
ents did not restore IL-17 production after Treg cell depletion
(Figure S2C). Therefore, the reduced IL-17 could not be attrib-
uted to inhibitory effects of enhanced IFN-g production when
Treg cells were depleted.Immunity 34, 409–421, March 25, 2011 ª2011 Elsevier Inc. 415
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Figure 6. Treg Cells Promote Th17 Cell Induction through Regulation of IL-2
(A–C) CD4+CD25– OT-II cells were transferred into wild-type or Foxp3.luciDTR4 recipients 1 day before immunization with OVA(323-339). Mice received two
injections of Diphtheria toxin (DT) given 24 hr apart starting on day1. Where indicated, mice received daily injections of 1 mg of anti-IL-2 or isotype control from
days 0 to 4 postimmunization. Draining LN cells were analyzed on day 7 for intracellular IL-17 in OT-II cells (A), absolute numbers of IL-17+OT-II cells (B), and
proportion of Foxp3+ cells out of total CD4+ cells (C).
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Treg Cells Promote Th17 Cells In Vivo through IL-2Treg Cells Promote Th17 Cell Development
by Regulating IL-2
Treg cells are highly dependent on IL-2 for maintenance and
expansion (Setoguchi et al., 2005). IL-2 has also been shown
to regulate Th17 cell induction (Laurence et al., 2007; Lohr
et al., 2006). Treg cells are early responders to IL-2 produced
by other activated T cells in vivo (O’Gorman et al., 2009), and
their consumption of IL-2 has been proposed as a mechanism
of regulation (Barthlott et al., 2005; de la Rosa et al., 2004;
Pandiyan et al., 2007). We therefore tested whether IL-2
blockade could impact Th17 cell induction in relation to Treg
cells. Neutralizing IL-2 antibody was administered for 5 days
from immunization of OT-II-transferred mice, via a protocol
previously demonstrated to block IL-2 activity on Treg cells
(Setoguchi et al., 2005; Suffner et al., 2010). IL-2 neutralization
itself did not alter the percentage of IL-17 producers in control
mice. However, when Treg cells were depleted at the time of
immunization, IL-2 neutralization significantly increased the
percentage of IL-17-producing cells (Figure 6A), as well as the
absolute numbers of IL-17+ cells, restoring these to similar
numbers as observed in control mice (Figure 6B). As expected,
Foxp3+ Treg cell frequencies were reduced when IL-2 was
neutralized in control mice (Figure 6C), confirming the known
importance of IL-2 for Treg cell homeostasis (Furtado et al.,
2002; Malek et al., 2002; Setoguchi et al., 2005). However, the
most dramatic effect was on the rapid expansion of Treg cells
after DT administration, which was almost completely inhibited
when IL-2 was neutralized (Figure 6C).
Treg cells could regulate IL-2 in two ways: by inhibiting IL-2
production (Thornton and Shevach, 1998) or by consuming
IL-2 (Barthlott et al., 2005; de la Rosa et al., 2004; Pandiyan
et al., 2007) by virtue of their constitutive expression of high-
affinity IL-2 receptor. Serum IL-2was not consistently detectable
by enzyme-linked immunosorbent assay (ELISA) on day 3 or day
7 postimmunization. We therefore analyzed the frequency of
IL-2-producing OT-II cells on day 3 postimmunization by using
conventional phorbol myristate acetate (PMA) and ionomycin
stimulation (Figure S3A) as well as stimulation with OVA(323-
339) peptide for 4 hr, followed by IL-2 secretion capture assay
(Figure 6D). Figure S3B shows IL-2 expression in non-OT-II
CD4+ T cells, which were used to set the analysis gates. Both
of these methods confirmed that Treg cell depletion did not
result in enhanced IL-2 production by recently activated
T cells. In fact, the majority of the OT-II cells were observed to
produce IL-2 regardless of whether Treg cells were present or
not, as we have observed before at early time points during
Th17 cell development (McGeachy et al., 2009). We then further
tested IL-2 secretion directly ex vivo, as well as after only 1 hr
peptide stimulation, at both 24 hr and 3 days postimmunization.(D–H) Three million CD4+CD25– OT-II cells were transferred into wild-type or Foxp
received two injections ofDiphtheria toxin on days1 and 0. Draining LN OT-II ce
with OVA(323-339) for 4 hr (D) or directly ex vivo and after 1 hr stimulation withOVA
and 36 hr postimmunization and quantitative RT-PCR was performed, values norm
were also assessed on day 3 postimmunization.
(I–K) The same experiment was repeated with daily injections of 1 mg anti-IL-2 or i
analyzed on day 3 postimmunization for OT-II cell expression of IL-17 (I), pSTAT
Data shown are representative of two to four experiments with three to four mice p
indicate mean; and (E) and (F) show mean ± SD.Again, there was no difference in the frequency of IL-2-
producing OT-II cells (Figure 6E) or of OT-II cells (Figure S3C).
Finally, we isolated total CD4+ and CD4 cells from draining
LN cells at 24 hr and 3 days postimmunization and performed
quantitative reverse-transcriptase polymerase chain reaction
(RT-PCR), which again showed no difference in total IL-2
mRNA between control and Treg cell-depleted mice (Figure 6F).
Therefore, we conclude that Treg cells did not regulate IL-2
production by developing Th17 cells in vivo.
IL-2 receptor engagement results in phosphorylation of signal
transducer and activator of transcription-5 (pSTAT5), and
pSTAT5 was required for inhibition of IL-17 by IL-2 (Laurence
et al., 2007). We therefore compared ex vivo pSTAT5 in OT-II
cells on day 3 postimmunization in the presence or absence of
Treg cells. The frequency of pSTAT5-positive OT-II cells was
increased when Treg cells had been depleted (Figure 6G). The
high-affinity IL-2 receptor subunit CD25 is upregulated in
recently activated T cells in response to IL-2 signaling in a
feed-forward manner (Kim et al., 2001). Corresponding with
increased pSTAT5, CD25 expression was also increased in the
absence of Treg cells (Figure 6H). We also observed pSTAT5
expression in Foxp3+ T cells at day 3 postimmunization (data
not shown), confirming previous reported data (O’Gorman
et al., 2009).
Because other factors such as IL-7 can activate STAT5, and
CD25 is also upregulated in response to CD28 costimulation,
we next confirmed that the changes observed after Treg cell
depletion were due to enhanced IL-2. When we analyzed IL-17
production at day 3, the effect of IL-2 neutralization was even
more marked than at day 7 (Figure 6I). When anti-IL-2 was
administered during Treg cell depletion and immunization, both
pSTAT5 and CD25 expression were markedly decreased
compared to isotype control-treated mice (Figures 6J and 6K).
Taken together, these data confirmed that one of the mecha-
nisms through which Treg cells promote Th17 cell development
was the consumption of IL-2, thereby reducing upregulation of
CD25 and activation of the STAT5 pathway.
DISCUSSION
Li et al. (2007) initially showed that T cells are a main source of
TGF-b for Th17 cell induction in vivo, although they did not
dissect which T cell populations are required. In vitro data sug-
gested that Treg cells support Th17 cell development and that
this may be through production of TGF-b (LeibundGut-Land-
mann et al., 2007; Veldhoen et al., 2006a). Cotransfer of Treg
cells with naive T cells in graft-versus-host disease or neo-self
autoimmune models results in increased frequencies of Th17
cells, although the mechanism was not clear from either study3.luciDTR4 recipients 1 day before immunization with OVA(323-339), and mice
lls were analyzed on day 3 postimmunization for IL-2 secretion after stimulation
(323-339) (E). CD4+ andCD4 cells were isolated from draining LN cells at 24 hr
alized to ubiquitin (F). Ex vivo pSTAT5 expression (G) and CD25 expression (H)
sotype control given from days 0 to 2 postimmunization. Draining LN cells were
5 (J), and CD25 (K).
er group; graphs show pooled data frommultiple experiments; horizontal bars
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enhancement of IL-17 by cotransferred Treg cells by using
a Th17 cell-inducing immunization protocol. Our data now
further show that Foxp3+ regulatory T cells are required for the
full generation of Th17 cell responses in vivo. However, we find
that TGF-b production by Treg cells is not required in vivo, in
contrast to suggestions from in vitro data.
Recent data argue that TGF-b is dispensable if Th1 cell and
Th2 cell responses are inhibited (Das et al., 2009). Treg cells
could certainly also perform this function, either directly or indi-
rectly via actions on antigen-presenting cells (APC). However,
we did not observe any effect of blocking Th1 cell-associated
cytokines IL-12 or IFN-g, nor did we find any evidence to support
the hypothesis that APC function was altered to favor a Th1 cell
rather than Th17 cell response. It was unexpected that depletion
of Treg cells did not lead to increased production of IFN-g in our
model. An increased activation state was observed in the recip-
ient CD4+Foxp3– T cell population, with greater proportions of
cells expressing CD44. Increased activation of CD4+ T cells
was also reported when Treg cells were depleted in nonimmu-
nized mice (Suffner et al., 2010). However, we did not consis-
tently see an increase in IFN-g, nor did IFN-g contribute to the
reduced IL-17 when Treg cells were depleted. Our model is opti-
mized toward Th17 cell induction, so few IFN-g+ cells are
routinely observed (McGeachy et al., 2009). Perhaps more
importantly, in this system Treg cells are not continuously
depleted and numbers return to normal within 1 week. Given
the high expression of CD44 by these recently expanded Treg
cells, it could be hypothesized that it is this return to active
duty of the Treg cell population that limits an overexuberant
Th1 cell response.
The cytokine IL-2 is produced by T cells early after activation
and has been shown to inhibit the generation of Th17 cells (Lau-
rence et al., 2007). The partial restoration of IL-17 production
when IL-2 was neutralized showed that regulation of IL-2
is one of the previously unappreciated mechanisms of action
of Foxp3+ Treg cells in promoting Th17 cells in vivo. The
percentage of IL-17-producing cells was not fully restored
compared to controls, although numbers were similar, suggest-
ing that there may be further additional mechanisms by which
Treg cells promote Th17 cell development at this early stage.
Treg cells could regulate IL-2 by twomechanisms: inhibition of
IL-2 production by activated T cells (Thornton and Shevach,
1998) or consumption of IL-2 to limit activated T cell exposure
to IL-2 (Barthlott et al., 2005; Pandiyan et al., 2007). It has also
been shown that both mechanisms could operate in the same
system in vitro (Barthlott et al., 2005). We were unable to detect
an increase in serum IL-2, although concentrations were below
assay sensitivity for most mice tested (data not shown).
However, we were able to show that Treg cell depletion did not
result in altered IL-2 production ex vivo or in response to general
or antigen-specific ex vivo activation. The propensity of OT-II
cells to produce IL-2 under this protocol further supports the
need for a mechanism to regulate IL-2 signaling in these cells
in order to allow Th17 cell development.
O’Gorman et al. (2009) have recently demonstrated that
Foxp3+ Treg cells rather than activated T cells are first
responders to, in other words consumers of, IL-2 after immuniza-
tion. We did confirm that a proportion of Foxp3+ cells are418 Immunity 34, 409–421, March 25, 2011 ª2011 Elsevier Inc.pSTAT5+ in our model (data not shown). Furthermore, the
reduced expansion of Treg cells after DT administration under
IL-2-neutralizing conditions supports the hypothesis that Treg
cells are consuming IL-2. In this regard, one could speculate
that the more rapid expansion of Treg cells in mice immunized
with OVA-CFA compared to naive mice is at least in part medi-
ated by the increased IL-2 production that occurs when T cells
are activated.
A clearer link between Treg cell depletion and increased IL-2
signaling in developing Th17 cells came from analysis of
ex vivo pSTAT5 and CD25 expression. During early activation,
IL-2 signaling results in further upregulation of the high-affinity
subunit of its own receptor, CD25 (Kim et al., 2001; Malek,
2008). When Treg cells were depleted, both pSTAT5 and CD25
were increased around 2-fold in the OT-II population. This effect
could be blocked by neutralizing IL-2, confirming that it was
specific to IL-2 and not because of other activation signals or
cytokines. These results, along with the IL-2 expression data,
led us to conclude that it is more likely that Treg cell consumption
of IL-2 supported early Th17 cell development.
After Treg cell depletion, the reduced frequency of IL-17-
producing OVA-specific cells in the dLN cells correlated well
with reduced frequency of these cells in the blood at day 10.
Hence, the effector response was impaired at the population
level. By using this OT-II transfer system of Th17 cell activation
in vivo, we have previously shown similar reduction of IL-17+
IL-23R-deficient effector cells in the blood correlating with
reduced ability to induce inflammation in the DTH response
(McGeachy et al., 2009). In seeming contrast to our results, Spar-
wasser and colleagues had previously shown enhanced DTH
responses in their DEREG mice when Treg cells are depleted
(Lahl et al., 2007). However, they used a hapten-based model
without CFA, most probably not Th17 cell dependent, and,
perhaps more importantly, Treg cells are continuously absent
up to and including the point of DTH challenge. In our mice,
Treg cell percentages were similar to wild-type at the time of
DTH challenge, and therefore our data do not directly contradict
the conclusion of Sparwasser and colleagues that Treg cells
modulate tissue-specific inflammation. Rather, we examined
the effects on Th17 cells when Treg cells are absent only during
primary challenge.
Foxp3+ Treg cells have been shown to convert into Th17 cells
under inflammatory conditions (Xu et al., 2007). In our study, the
cells of interest (OT-II) did not express DT receptors, so Foxp3+
cells in that population would not be depleted. However, we
depleted CD25hi cells before transfer to avoid transferring Treg
cells with naiveOT-II cells. In addition, we have previously shown
that in this system the OT-II cells remain negative for Foxp3
(McGeachy et al., 2009). Therefore in this system, the Treg cells
are a separate population to the responding Th17 cells.
Our results suggested that Treg cells played a limited role in
maintaining Th17 cell phenotype, particularly in mice that were
immunized after receiving in vitro polarized Th17 cells. In this
scenario, immunization with CFA induces inflammatory cyto-
kines including IL-23, as well as providing cognate antigen
(Veldhoen et al., 2006b), representing the activation phase of
the response. It was not clear why there was a small decrease
in the proportion of IL-17+ cells when recipient mice were not
immunized. After Treg cell depletion in naive mice, endogenous
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of Treg cells. We speculate that this may induce competition for
survival factors or increase Th17 cell-regulating factors in the
absence of Th17 cell-enhancing cytokines such as IL-23.
Previous studies have shown conversion of Th17 cells to Th1
cells after transfer in vivo (Bending et al., 2009; Martin-Orozco
et al., 2009). We did not observe this, but we used T cells that
had undergone two rounds of stimulation with TGF-b and IL-6
in vitro and were transferred into lymphoid-sufficient hosts.
This concurs with the recent study from Nurieva et al. (2009)
showing that transfer into a lymphopenic environment results
in greater Th1 cell conversion than transfer into lymphoid-
sufficient hosts. Importantly, Treg cell depletion on day 4 postim-
munization had little effect on IL-17 induction. Therefore
we conclude that the time frame in which Treg cells promote
Th17 cell development and/or function is probably quite short,
fitting with our previous data showing that IL-23 signals are
crucial from day 4 and 5 of the immune response to promote
subsequent Th17 cell effector cell differentiation (McGeachy
et al., 2009). This also allows for the possibility that Treg cells
may inhibit Th17 cell responses during the later phase of
inflammation.
In many of the inflammatory disease models now associated
with Th17 cells, including experimental autoimmune encephalitis
(EAE) and arthritis, Treg cells have been shown to limit immuno-
pathology: the depletion of Treg cells results in exacerbated
disease or reduced threshold for disease initiation (Sakaguchi
and Powrie, 2007). It may seem surprising that Treg cells would
promote inflammatory cells. However, our finding that Treg cell
promotion of Th17 cell development was mainly restricted to
the initial few days after immunization suggests that Treg cells
will not continually promote Th17 cell inflammatory function.
These observations are also in agreement with findings from
several models of inflammation caused by deficiency of Treg
cells: this type of inflammation is most often dominated by
a Th1 cell response. One notable exception is the IL-2-deficient
mouse, in which Treg cells are almost nonexistent; in this mouse,
Th17 cells dominate the overwhelming inflammatory disease. In
addition, it should be noted that use of anti-CD25 to deplete Treg
cells could also allow Th17 cell development by blocking IL-2
signaling.
The immune system is a constant balancing act, and this
seems to be yet another example: by consuming IL-2, Treg cells
protect developing Th17 cells from IL-2’s inhibitory effects, but in
doing so the Treg cells are also promoting their own expansion
(Furtado et al., 2002). Because the stimulus of inflammation (in
the case of infection) is controlled by the Th17 cell response,
the expanded Treg cells are now better able to do their part
to control the inflammation and restore homeostasis. In the
case of chronic autoimmune inflammation, it is clear that this
process has become dysregulated, and therapeutic interven-
tions become necessary to restore balance.EXPERIMENTAL PROCEDURES
Mice
Foxp3.luciDTR4 and Foxp3.luciDTR5 mice were generated and provided by
G. Hammerling, DKFZ, Heidelberg, Germany. Mice were maintained on a
heterozygous background and screened on basis of GFP expression.GFP-negative littermates were used as controls. Tgfb1f/n Foxp3-cre mice
were generated and maintained at Memorial Sloan Kettering Cancer Center.
OT-II and CD45.1+ mice were obtained from Jackson Research Labs and
interbred at Merck (formerly Schering Plough Biopharma). RAG2-deficient
mice were obtained from Taconic. Animals were maintained in a barrier SPF
facility and all animal procedures were approved by the Merck (formerly
Schering Plough Biopharma) IACUC committee, in accordance with AAALAC
guidelines.
Reagents
The following flow cytometry antibodies were purchased from BD Biosci-
ences: CD4 (RM4-5), CD45.1 (A20), CD44 (IM7), IFN-g (XMG1.2), IL-17
(TC11-18H10), and pSTAT5(pY694). Intracellular cytokine staining was per-
formed with Cytofix-cytoperm kit from BD according to the manufacturer’s
instructions. pSTAT5 staining was performed with BD Phosflow kit according
to the manufacturer’s instructions. We purchased from eBioscience Foxp3
(FJK-16 s), used with Foxp3 staining kit from eBioscience according to the
manufacturer’s instructions. Anti-IL-2 (S4B6) was obtained from BioXCell;
anti-IFN-g (XMG1.2) and isotype control (rat IgG1) Abs were generated in-
house. OVA(323-339) was obtained from Biosynthesis Inc (Lewisville, TX).
Th17 Cell Induction In Vivo and Analysis
For Treg cell depletion experiments, 105 CD45.1+ OT-II CD4+CD25-depleted
(Miltenyi Biotec CD4+CD25+ selection kit) T cells were transferred intrave-
nously into CD45.2+ wild-type or Foxp3.lucDTR recipient mice 1 day before
immunization with 100 mg OVA(323-339) in 100 ml complete Freund’s adjuvant
(IFA containing 50 mg heat-killed Mycobacterium tuberculosis H37Ra) (both
Difco, MI) subcutaneously in the hind flanks. For cotransfer experiments,
one million CD45.1+ OT-II CD4+CD25-depleted T cells were transferred intra-
venously into CD45.2+ RAG2-deficient mice 1 day before immunization with
100 mg OVA(323-339) in 100 ml complete Freund’s adjuvant. Phenotype of
CD45.1+ OT-II T cells and Foxp3+ Treg cells in draining LN cells was assessed
by flow cytometry and gating on live CD4+ cells. For cytokine analysis, draining
LN cells were cultured in complete medium (RPMImedia containing 10%FCS,
supplemented with Pen-Strep, L-glutamine, HEPES, sodium pyruvate, and
2-ME) with 50 ng/ml PMA and 500 ng/ml ionomycin (both Sigma-Aldrich) in
the presence of Golgiplug (BD Biosciences) for 4 hr followed by staining and
analysis by flow cytometry. For pSTAT5 analysis, 3 3 106 CD45.1+ OT-II
CD4+CD25-depleted T cells were transferred intravenously into CD45.2+
wild-type or Foxp3.lucDTR recipient mice, which were immunized as before.
Draining LN cells were removed on day 3 and single-cell suspensions were
immediately obtained by mashing into BD Phosflow Fix buffer. After a further
10min incubation at 37C, cells were washed and permeabilized and antibody
staining was performed as per BD Phosflow manufacturer’s instructions. IL-2
secretion was detected on day 3 by stimulating the lymph node cells for 4 hr
with 5 mg/ml OVA(323-339), followed by detection of secreted IL-2 with the
IL-2 secretion assay detection kit (Miltenyi Biotec).
Treg Cell Depletion
Mice received two injections ofDiphtheria toxin isolated from corynebacterium
diphtheriae (Sigma-Aldrich, MO) in PBS given 1 day apart by the intraperito-
neal route, at a dose of 15 ng per g body weight.
In Vitro Th17 Cell Induction and Transfer
OT-II LN and spleen cells were stimulated with OVA(323-339) in the presence
of 10 ng/ml TGF-b, 100 ng/ml IL-6 (both from R&D), 5 mg/ml anti-IFN-g
(XMG1.2), and 2.5 mg/ml anti-IL-2 (JES6-1A12) in RPMI media containing
10% FCS, supplemented with Pen-Strep, L-glutamine, HEPES, sodium pyru-
vate, and 2-ME. Cells were restimulated under the same conditions with the
addition of CD4-depleted splenocytes on day 6 of culture. On day 9, IL-17
production was assessed by intracellular cytokine staining after stimulation
with PMA and ionomycin for 4 hr. CD4+ cells were enriched before transfer
by positive selection with anti-CD4 microbeads (Miltenyi Biotec) according
to manufacturer’s instructions.
Delayed Type Hypersensitivity
Immunized recipients of OT-II cells were challenged in one hind footpad with
100 mg ovalbumin in saline; the contralateral hind footpad was injected withImmunity 34, 409–421, March 25, 2011 ª2011 Elsevier Inc. 419
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Treg Cells Promote Th17 Cells In Vivo through IL-2saline only. Foot thickness was measured 24 hr later with calipers (Mitutoyo),
and data are shown as increase in OVA-challenged foot thickness over the
saline control for the same mouse.
Statistics
Statistical analysis was done by Student’s t test (two groups) or one-way
ANOVA (more than two groups) with Graphpad Prism software. Where shown,
error bars indicate standard deviation.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found with this
article online at doi:10.1016/j.immuni.2011.02.011.
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